Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer
Status:
Completed
Trial end date:
2011-01-18
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for
their growth.
PURPOSE: This phase II trial is studying the effectiveness of sorafenib in treating patients
who have metastatic or recurrent prostate cancer that has not responded to previous hormone
therapy.